We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.
- Authors
Sehouli, J; Oskay-Ozcelik, G; Kühne, J; Stengel, D; Hindenburg, H-J; Klare, P; Heinrich, G; Schmalfeldt, B; Mertens, H; Camara, O; Lichtenegger, W; Ovarian Cancer Study Group of the Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO)
- Abstract
The obvious benefit of pegylated liposomal doxorubicin (PLD) for tumour control in recurrent ovarian cancer is frequently offset by severe palmar-plantar erythrodysesthesia (PPE). There is evidence that dose reduction from 50 to 40 mg/m(2) reduces the incidence of PPE without compromising cytotoxic activity. We set out to investigate whether biweekly application further improves the therapeutic index of PLD.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Vol 17, Issue 6, p957
- ISSN
0923-7534
- Publication type
Journal Article
- DOI
10.1093/annonc/mdl079